Funding for this research was provided by:
Received: 10 August 2022
Accepted: 24 October 2022
First Online: 8 November 2022
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Yale University Human Investigation Committee and the Yale-New Haven Hospital Radiation Safety Committee. Written informed consent was obtained from all subjects.
: Not applicable.
: M.N., J.-D. G., N.B.N., S.H., Y.H., and M.-K. C. have no conflicts of interest to report. S.J.F. is currently a full-time employee and shareholder of AbbVie. R.P.M., J.M., S.K., J.-M.N., H.K., and A.S. are current employees of UCB Pharma. J.H. was employee of UCB Pharma at the time this work was conducted and is currently a full-time employee of Tranquis Therapeutics, Inc. R.E.C. has received research support from Astellas Pharma, Astra-Zeneca, Bristol Myers Squibb, Lilly, Pfizer, Taisho Pharmaceutical, and UCB Pharma, outside of the submitted work.